Coronavirus Business Continuity

U.S. Temporary Modification to Product Indications for Use

To address coronavirus (COVID-19) and per the U.S. Food and Drug Administration, LivaNova is now permitted to modify cardiopulmonary products indications for use to include ECMO therapy beyond six hours. This applies to the following products:

S5™ heart-lung machine
CP5™ centrifugal pump driver
Revolution™ centrifugal pump
Inspire™ family of oxygenators
EOS™ PMP oxygenator
LifeSPARC™ pump and controller
TandemHeart™ pump and controller
TandemLung™ oxygenator
ProtekDuo™ cannulae
EasyFlow™ Aortic Cannula
Remote Access Perfusion (RAP) Femoral Venous Cannula

FAQs – Use of LivaNova ECMO/CPB Devices for COVID-19 Patients
View the full press release here.

VNS Therapy™ for Epilepsy

We understand the additional challenges that COVID-19 has created for people with epilepsy and especially those with uncontrolled seizures. We encourage you to stay in contact with your healthcare team in order to make the best possible decisions both to optimize epilepsy care for you or your loved one and also to minimize the risks of COVID-19.

Learn more

First Name:
Last Name:
Email:
I am:
Country:
State / Province / Other:
City:
Phone Number:
Message:
Privacy Policies:	I read and agree with LivaNova Privacy Policies